Compare TSHA & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSHA | CHCO |
|---|---|---|
| Founded | 2019 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2020 | 1995 |
| Metric | TSHA | CHCO |
|---|---|---|
| Price | $6.02 | $144.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | $11.63 | ★ $132.50 |
| AVG Volume (30 Days) | ★ 2.6M | 94.2K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | 5.56 | ★ 13.18 |
| EPS | N/A | ★ 4.55 |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | $5.16 |
| Revenue Next Year | $1,152.42 | $3.12 |
| P/E Ratio | ★ N/A | $31.65 |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $2.72 | $113.21 |
| 52 Week High | $7.30 | $148.99 |
| Indicator | TSHA | CHCO |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 56.75 |
| Support Level | $5.28 | $143.67 |
| Resistance Level | $6.88 | $148.28 |
| Average True Range (ATR) | 0.34 | 2.12 |
| MACD | -0.01 | -0.73 |
| Stochastic Oscillator | 31.82 | 37.86 |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.